Uncaged

WATCH: SinglePoint CEO Wil Ralston Joins Bant Breen on the Uncaged Interview

Retrieved on: 
Friday, January 20, 2023
SinglePoint, Inflation Reduction Act of 2022, Solar energy, Indoor air quality, Human, OTCQB, Government, Politics, The Company, K-12, Acquisition, Inflation, Uncaged, Renewable energy

PHOENIX, Jan. 20, 2023 /PRNewswire/ -- SinglePoint, Inc. (OTCQB: SING) ("SinglePoint'' or "the Company"), a renewable solar energy and sustainable solutions provider, announced today that Wil Ralston, CEO of SinglePoint Inc., on The Uncaged Show to discuss how the Company is helping commercial, government, and residential consumers adopt sustainable solutions for Indoor Air Quality and solar energy. The Uncaged show celebrates the thought leadership of today's top business leaders.

Key Points: 
  • This program gives a voice to the great leaders shaping today's business world and leading the way for tomorrow's commerce.
  • Mr. Ralston noted that everyone at SinglePoint improved their ability to make decisions, execute those decisions quickly and learn from those choices.
  • As a public company's CEO, Wil Ralston acknowledges that general market instabilities create business fears.
  • SinglePoint continues to serve its customers successfully while expanding its footprint through organic growth, reflected in shareholder value and Company size.

DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study

Retrieved on: 
Wednesday, June 1, 2022
Health, Medical Devices, Surgery, Clinical Trials, Research, Science, Cardiology, Elixir, Paragon, Stent, Kung, Restenosis, MACE, Pulsatile flow, Champaign County, Illinois, ISAR, IVUS, HIV disease progression rates, Torsion, Uncaged, Rotation, Medicine, University, Sale, Patient, Philippe Khorsand, Compliance, CE marking, Coronary artery disease, Heart, Clinical, LAD, Comparison, Pharmaceutical industry, Medical device, Wood drying, MD

The DynamX Bioadaptor is the first drug-eluting coronary artery implant that adapts to vessel physiology by incorporating flexible uncaging elements into its design.

Key Points: 
  • The DynamX Bioadaptor is the first drug-eluting coronary artery implant that adapts to vessel physiology by incorporating flexible uncaging elements into its design.
  • Computational modeling also indicated that peak rotational stress for the bioadaptor decreased by 70 percent with uncaging of the bioadaptor.
  • The DynamX Mechanistic Clinical Study previously showed that the bioadaptor enabled positive adaptive remodeling, preserving the vessel lumen to accommodate disease progression, as well as a return towards baseline vessel angulation and a strong safety profile.
  • This recent analysis now demonstrates the ability of the device to twist along with the vessels natural motion, and in doing so, subsequently reduce vessel stress.